UCB will use Cradle’s AI-driven protein design platform in selected discovery projects, from hit generation through preclinical readiness, expanding its digital antibody engineering program.
|Articles|June 19, 2019
Partnership Forms to Standardize Cell and Gene Therapy Supply Chain Solutions
Author(s)BioPharm International Editors
Be The Match BioTherapies and TrakCel have announced a collaboration to provide integrated solutions for companies developing cell and gene therapies.
Advertisement
Solutions provider, Be The Match BioTherapies, and software developer, TrakCel, have announced a collaboration to provide integrated solutions for companies developing cell and gene therapies in a June 18, 2019 press release.
The strategic partnership is aimed at combining services and technology platforms that will help improve operations of cell and gene therapy supply chain. The companies will identify the challenges facing developers of cell and gene therapies to be able to provide the optimal integrated solutions.
“Be The Match BioTherapies and TrakCel share the goal of ensuring that the next generation of cell and gene therapies can be developed efficiently and delivered to patients safely and reliably,” said Chris McClain, vice-president, sales and new business development, Be The Match BioTherapies, in the release. “This collaboration will allow us to develop the custom solutions best suited for each individual program and patient population.”
“Clinical and commercial advances in cell and gene therapies continue to progress dramatically. However, the resultant increases in complexity and stakeholders involved in the supply chain can leave it stretched and fragmented, potentially exposing patients to unnecessary risks,” added Ravi Nalliah, CEO, TrakCel. “As a result, TrakCel is continuing to sign partnerships with relevant industry providers to ensure the ever-growing supply chain can be effectively managed. This specific partnership with Be The Match BioTherapies will enable us to provide a more standardized and streamlined cell and gene therapy development process. That, in turn, will accelerate the delivery of vital new therapies to patients.”
Source:
Advertisement
Related to this article
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
ProBio grants AbTis exclusive global rights to a discovery-stage oncology antibody for development as a site-specific antibody-drug conjugate.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5